Titan Pharmaceuticals, Inc.

TTNPNASDAQHealthcare

$2.34

$-0.30(-11.36%)

Market Cap$3112748

P/E Ratio—

52W High$15.15

52W Low$2.33

Avg Volume99K

Open$2.55

Beta1.38

Overview

Titan Pharmaceuticals, Inc. (TTNP) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

ttnp · stock forecast · 4 analysts (3M) · FMP · updated Jan 30, 2026

Analyst Rating & Consensus

Based on 4 Wall Street analysts in the past 3 months

Buy

4 analysts

consensus

Rating Breakdown

Strong Buy

Buy

Hold

Sell

Strong Sell

Total: 4 · Buy rate: 50.0%

12-Month Price Target

High

$0.00

Consensus

$0.00

+0.0% upside

Low

$0.00

Median: $0 · Last Close: $1.55

The Titan Pharmaceuticals, Inc. (TTNP) analyst consensus is Buy, based on ratings from 4 Wall Street analysts over the past 3 months. The average 12-month TTNP price target is $0.00, representing +0.0% upside from the current price of $1.55.

Short-Term Price Prediction

Low Activity

Algorithmically generated · Updated daily

Date	Predicted Price	Change	Min	Max
2026-06-09	$1.47	↓ 5.00%	$1.41	$1.54

1-day model range: $1.41–$1.54. Peak: $1.54 (-5.00%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

Year	Low	Avg Price	High	Change
2027	$1	—	$1	-50.0%
2028	$1	—	$1	-62.5%
2029	$0	—	$1	-67.2%
2030	$0	—	$1	-69.2%
2031	$0	—	$1	-70.2%

Confidence:Very Low

⚠️ 2027 projections carry Very Low confidence. Treat as directional guidance only.

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

🚫

Insufficient Trading Activity — Sentiment Signals Disabled

This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.

RSI (14)29.2

MACDBEARISH

Moving Averages · TTNP · Jun 8, 2026

Simple Moving Average (SMA)

MA 5$1.70SELL

MA 10$1.70SELL

MA 20$1.95SELL

MA 50$2.96SELL

MA 100$3.69SELL

MA 200$3.88SELL

Current $TTNP · Price above MA = BUY signal

Exponential Moving Average (EMA)

EMA 5$1.67SELL

EMA 10$1.76SELL

EMA 20$2.03SELL

EMA 50$2.74SELL

EMA 100$3.31SELL

EMA 200$3.74SELL

Current $TTNP · Price above MA = BUY signal

How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:

Date	Brokerage	Action	Rating
2022-05-25	Maxim Group	Downgrade ↓	Buy→Hold
2021-02-17	Maxim Group	Upgrade ↑	Hold→Buy
2020-08-17	Maxim Group	Downgrade ↓	Buy→Hold
2019-10-23	Maxim Group	Upgrade ↑	Hold→Buy
2017-11-10	Roth Capital	Downgrade ↓	Buy→Neutral
2014-07-07	Highline Research	Maintains	Buy→Buy
2012-08-21	Burrill & Company	Maintains	Market Outperform→Outperform

Maxim Group2022-05-25

Downgrade ↓

Buy→Hold

Maxim Group2021-02-17

Upgrade ↑

Hold→Buy

Maxim Group2020-08-17

Downgrade ↓

Buy→Hold

Maxim Group2019-10-23

Upgrade ↑

Hold→Buy

Roth Capital2017-11-10

Downgrade ↓

Buy→Neutral

Highline Research2014-07-07

Maintains

Buy→Buy

Burrill & Company2012-08-21

Maintains

Market Outperform→Outperform

Wall Street analysts have recently issued updated ratings on Titan Pharmaceuticals, Inc. (TTNP) stock. Of the recent 7 rating actions, 2 were upgrades and 3 were downgrades. 4 analysts currently cover TTNP.

Analyst Recommendation Trends

Buy ratings1 → 0↓ 1

Hold ratings0 → 1↑ +1

Sell ratings0 → 0

TTNP analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$0M

↓ 98.8% YoY

Revenue Next Year

$12M

↑ 6094.3% YoY

EPS This Year

$-18.20

EPS Next Year

$-16.60

↓ 8.8% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast TTNP EPS of $-18.20 for the current fiscal year, based on estimates from 1 analysts. The TTNP revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The TTNP stock forecast is supported by two independent data sources: analyst consensus ratings from 4 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus TTNP price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.

The TTNP short-term stock prediction for tomorrow is $1.47 (-5.00%). The TTNP stock prediction for 2030 projects a range of $0–$1.

Titan Pharmaceuticals, Inc. trades on NASDAQ under the ticker TTNP. The TTNP stock outlook for 2027 is broadly positive, supported by a Buy consensus among 50% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Earnings Revenue PE Ratio Financials Market Cap Insider Trades Dividends Price History

Frequently asked questions

TTNP forecast · 8 questions

According to 4 Wall Street analysts, the average 12-month TTNP price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $1.55.

TTNP price targetWhat is TTNP price targetTTNP analyst price targetTTNP 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.